Could a common gout drug help people with type 1 diabetes?
NCT ID NCT07247734
First seen Jan 09, 2026 · Last updated Jun 21, 2026 · Updated 26 times
Summary
This study tests whether colchicine, a drug used for gout, can improve how the body uses insulin in people with type 1 diabetes who have low-grade inflammation. 26 adults will receive either colchicine or a placebo for four weeks, and their insulin sensitivity will be measured using a clamp procedure. The goal is to see if reducing inflammation can help manage blood sugar better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region 2900
RECRUITINGGentofte Municipality, 2400, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine
What this could lead to
If it works, this could point toward a new way to improve insulin sensitivity in people with type 1 diabetes, potentially reducing complications.
What could go wrong
This is a small, early-phase trial with only 26 participants. The effect may be small or not clinically meaningful, and colchicine can cause gastrointestinal side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.